|
|
Vaccine Detail
|
MART-1, tyrosinase and MAGE-A6 Autologous DC Vaccine |
| Vaccine Information |
- Vaccine Name: MART-1, tyrosinase and MAGE-A6 Autologous DC Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: MART-1, tyrosinase and MAGE-A6 (NCT01622933)
- Immunization Route: Intradermal injection (i.d.)
- Description: Autologous dendritic cells (DC) are transduced with the MART-1, tyrosinase and MAGE-A6 (melanoma associated antigens, MAA) genes for melanoma patients. Some patients also receive interferon-alfa 2b (IFN) intravenously. (NCT01622933)
|
| Host Response |
|
|
| References |
NCT01622933: Multiple Antigen-Engineered DC Vaccine for Melanoma [https://clinicaltrials.gov/study/NCT01622933]
|
|
